Chargement en cours...
Bardoxolone methyl: drug development for diabetic kidney disease
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies....
Enregistré dans:
| Publié dans: | Clin Exp Nephrol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Singapore
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497696/ https://ncbi.nlm.nih.gov/pubmed/32594372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-020-01917-5 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|